These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 19249182)

  • 1. Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients.
    Van Wart SA; Andes DR; Ambrose PG; Bhavnani SM
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):409-14. PubMed ID: 19249182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doripenem monohydrate, a broad-spectrum carbapenem antibiotic.
    Matthews SJ; Lancaster JW
    Clin Ther; 2009 Jan; 31(1):42-63. PubMed ID: 19243706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility.
    Roberts JA; Lipman J
    Crit Care Med; 2013 Feb; 41(2):489-95. PubMed ID: 23263583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration.
    Roberts JA; Udy AA; Bulitta JB; Stuart J; Jarrett P; Starr T; Lassig-Smith M; Roberts NA; Dunlop R; Hayashi Y; Wallis SC; Lipman J
    J Antimicrob Chemother; 2014 Sep; 69(9):2508-16. PubMed ID: 24879665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic assessment of doripenem in peritoneal fluid against Gram-negative organisms: use of population pharmacokinetic modeling and Monte Carlo simulation.
    Ikawa K; Morikawa N; Ikeda K; Ohge H; Sueda T
    Diagn Microbiol Infect Dis; 2008 Nov; 62(3):292-7. PubMed ID: 18703305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.
    Samtani MN; Flamm R; Kaniga K; Nandy P
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2360-4. PubMed ID: 20385857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers.
    Cirillo I; Vaccaro N; Turner K; Solanki B; Natarajan J; Redman R
    J Clin Pharmacol; 2009 Jul; 49(7):798-806. PubMed ID: 19553404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics of doripenem in critically ill patients with ventilator-associated Gram-negative bacilli pneumonia.
    Jaruratanasirikul S; Wongpoowarak W; Kositpantawong N; Aeinlang N; Jullangkoon M
    Int J Antimicrob Agents; 2012 Nov; 40(5):434-9. PubMed ID: 22959555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients.
    Ikawa K; Morikawa N; Uehara S; Monden K; Yamada Y; Honda N; Kumon H
    Int J Antimicrob Agents; 2009 Mar; 33(3):276-9. PubMed ID: 19095418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of doripenem in Japanese subjects and Monte-Carlo simulation for patients with renal impairment.
    Matsuo Y; Ishibashi T; Kubota R; Wajima T
    J Infect Chemother; 2015 Feb; 21(2):123-9. PubMed ID: 25487084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients with Sepsis.
    Rahbar AJ; Lodise TP; Abraham P; Lockwood A; Pai MP; Patka J; Rabinovich M; Curzio K; Chester K; Williams B; Morse B; Chaar M; Huang V; Salomone J
    Surg Infect (Larchmt); 2016 Dec; 17(6):675-682. PubMed ID: 27841954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead.
    Tsuji BT; Okusanya OO; Bulitta JB; Forrest A; Bhavnani SM; Fernandez PB; Ambrose PG
    Clin Infect Dis; 2011 Jun; 52 Suppl 7():S513-9. PubMed ID: 21546628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doripenem: position in clinical practice.
    Dedhia HV; McKnight R
    Expert Rev Anti Infect Ther; 2009 Jun; 7(5):507-14. PubMed ID: 19485791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem.
    Bhavnani SM; Hammel JP; Cirincione BB; Wikler MA; Ambrose PG
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3944-7. PubMed ID: 16127078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients.
    Ikawa K; Morikawa N; Urakawa N; Ikeda K; Ohge H; Sueda T
    J Antimicrob Chemother; 2007 Dec; 60(6):1395-7. PubMed ID: 17884833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of carbapenems in the treatment of severe nosocomial respiratory tract infections.
    Joseph J; Rodvold KA
    Expert Opin Pharmacother; 2008 Mar; 9(4):561-75. PubMed ID: 18312158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Removal of doripenem during hemodialysis and the optimum dosing regimen for patients undergoing hemodialysis.
    Tanoue K; Nishi K; Kadowaki D; Hirata S
    Ther Apher Dial; 2011 Jun; 15(3):327-33. PubMed ID: 21624085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic analysis of doripenem in elderly patients with nosocomial pneumonia.
    Harada M; Inui N; Suda T; Nakamura Y; Wajima T; Matsuo Y; Chida K
    Int J Antimicrob Agents; 2013 Aug; 42(2):149-54. PubMed ID: 23684002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of intravenous infusion of doripenem.
    Redman R; File TM
    Clin Infect Dis; 2009 Aug; 49 Suppl 1():S28-35. PubMed ID: 19619019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doripenem (Doribax)--a new parenteral carbapenem.
    Med Lett Drugs Ther; 2008 Jan; 50(1278):5-7. PubMed ID: 18219262
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.